ABSTRACT

Prostate specific antigen has been used worldwide the most common cancer marker for prostate cancer. PSA specific for prostate tissue but not specific for prostate cancer. Widespread and increase use of PSA-based screening programs lead to increased number of low grade prostate cancer diagnosis which will never return to clinically significant cancer. This issue enhance the detection rates of prostate cancer but also increased the number of unnecessary biopsies. As a result, need for determine the clinically important prostate cancer diagnosis and can prevent unnecessary prostate biopsies. Therefore, there is a urgent need for a new prostate marker, more accurate than PSA to be used in diagnosis of prostate cancer. PCA3 is a prostate-specific noncoding mRNA that is highly over expressed in more than 95% of primary PCa specimens and PCa metastases. The purpose of this review is to discuss the place of PCA3 reputation at prostate cancer diagnosis by the current literature.